Abstract
Liposomes are widely used as drug delivery systems and several liposome-based nanomedicines have been approved for clinical use. Cell penetrating peptides (CPPs) have been decorated onto nanoparticulated vesicle such as liposomes to further improve the intracellular delivery efficiency. However, the poor selectivity of CPPs hindered their application, especially in the in vivo application. To resolve this issue, several strategies have been developed, including shielding and environment-triggered deshielding of CPPs as well as designing of environment-responsive CPPs and specific- targeting CPPs and last but not least, combination strategy. In this review, the abovementioned strategies were discussed.
Keywords: Cell penetrating peptides, liposomes, intelligent.
Current Pharmaceutical Biotechnology
Title:Cell-penetrating Peptide-based Intelligent Liposomal Systems for Enhanced Drug Delivery
Volume: 15 Issue: 3
Author(s): Huile Gao, Qianyu Zhang, Zhiqiang Yu and Qin He
Affiliation:
Keywords: Cell penetrating peptides, liposomes, intelligent.
Abstract: Liposomes are widely used as drug delivery systems and several liposome-based nanomedicines have been approved for clinical use. Cell penetrating peptides (CPPs) have been decorated onto nanoparticulated vesicle such as liposomes to further improve the intracellular delivery efficiency. However, the poor selectivity of CPPs hindered their application, especially in the in vivo application. To resolve this issue, several strategies have been developed, including shielding and environment-triggered deshielding of CPPs as well as designing of environment-responsive CPPs and specific- targeting CPPs and last but not least, combination strategy. In this review, the abovementioned strategies were discussed.
Export Options
About this article
Cite this article as:
Gao Huile, Zhang Qianyu, Yu Zhiqiang and He Qin, Cell-penetrating Peptide-based Intelligent Liposomal Systems for Enhanced Drug Delivery, Current Pharmaceutical Biotechnology 2014; 15 (3) . https://dx.doi.org/10.2174/1389201015666140617092552
DOI https://dx.doi.org/10.2174/1389201015666140617092552 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Novel Strategies of Regenerative Medicine Using Chemical Compounds
Current Medicinal Chemistry Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism In Silico Prediction and Validation of Oxygen-Regulated Protein N-myc Downstream Regulated Gene 3 and Virtual Screening of Competitive Inhibitors of L-Lactate as Therapeutics
Letters in Drug Design & Discovery Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Preliminary Analysis of Anti-proliferative, Apoptotic, and Anti-migratory Effects llw-3-6 in Skov-3 Ovarian Cystadenocarcinoma Cell Line
Letters in Drug Design & Discovery Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets A New Twist in Cellular Resistance to the Anticancer Drug Bleomycin-A5
Current Drug Metabolism Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Molecular Mechanisms Mediating Nociceptin/Orphanin FQ Receptor Signaling, Desensitization and Internalization
Current Molecular Pharmacology Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery Direct Conversion of Dermal Fibroblasts into Neural Progenitor Cells by a Novel Cocktail of Defined Factors
Current Molecular Medicine